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Objectives: To evaluate the cost-effectiveness of dasatinib versus nilotinib and 
high-dose imatinib (600 or 800 mg) for people with chronic myeloid leukemia (CML) 
in chronic, accelerated and blast phase (CP, AP and BP), which are resistant or intoler-
ant to normal-dose imatinib, from the perspective of the Chinese healthcare sys-
tem. MethOds: A Markov cohort model was adapted to Chinese treatment practice. 
Clinical and utility data were taken mostly from the literature by a MEDLINE search. 
Costs were based on local charges. The primary output was reported in terms of 
incremental cost-effectiveness ratios (ICERs). Univariate and probabilistic sensitiv-
ity analyses were performed to examine the robustness of the model output. The 
impact of patient assistance program (PAP, buy three- month and get nine-month 
free) was assessed. Results: In chronic phase, the base case analysis showed the 
dominance of dasatinib versus nilotinib and imatinib 800 mg strategies because 
dasatinib gained more quality-adjusted life years (QALYs) with lower costs. For 
CML-CP patients, dasatinib is expected to provide more QALYs with more costs in 
comparison with imatinib 600 strategy, yielding an ICER of ¥369,767 /QALY. When 
PAP was available, the ICER of dasatinib versus 600 mg imatinib was ¥101,453, and 
nilotinib and 800 mg imatinib were dominated in patients with CP. When 3 times 
per Capita GDP of China (¥125,414 /QALY) according to WHO recommendations was 
used as the threshold and PAP was provided, dasatinib achieved about 90% probabili-
ties of cost-effectiveness in chronic phase. The uncertainties could be contributed 
to the costs of drugs. cOnclusiOns: The results indicate that PAP could notably 
improve the cost-effectiveness of dasatinib versus nilotinib and high-dose imatinib 
among imatinib-resistant or intolerant CML patients in China. Dasatinib is likely to 
be cost-saving versus nilotinib or imatinib 800 mg strategies in CML-CP patients.
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Objectives: Chronic Lymphocytic Leukaemia (CLL) is an indolent progressive 
hematologic disease. Current treatments for CLL are not curative and subjects 
become increasingly resistant to subsequent therapies. Patients relapsing after 
a disease-free period shorter than 2 years have an anticipated overall survival of 
45% at 3 years. Idelalisib + rituximab is improving overall and progression-free 
survival compared to rituximab + placebo in early (< 2 years) relapsed CLL patients. 
This trial was stopped early because of overwhelming efficacy. We estimated the 
cost-effectiveness of Idelalisib + rituximab in the French context. MethOds: A 
partitioned survival model was used to compare Idelalisib + rituximab to currently 
available treatments in France: alemtuzumab, bendamustine-rituximab and ibru-
tinib for CLL patients with early relapse and fludarabine-cyclophosphamide-ritux-
imab, bendamustine-rituximab and ibrutinib for CLL patients with late relapse. 
Because of the lack of an identifiable trial network and the presence of single 
arm trials, we used an innovative approach for comparing survivals. In essence, 
the modelling was based on fitting a general survival parametric function for all 
treatments, and then adjusting the scale parameters of the function to fit the 
observed survivals in each study (i.e.”common gamma approach”). Time horizon 
was 10 years. Utilities associated with different stages of disease were based on 
data from the literature. French direct medical costs were used. Outcomes and 
costs were discounted at 4%. Price for idelalisib was the price used in the early 
access program in France. Results: Idelalisib + rituximab was associated with 
incremental cost-effectiveness ratios of 30 480 € /QALY in early relapse and 31 
312 € /QALY in late relapse. Sensitivity analyses showed that the result was highly 
sensitive to the efficacy of idelalisib partly explained by the immaturity of the 
survival data coming from a clinical study with early termination. cOnclusiOns: 
Idelalisib is a cost-effective option for the treatment of early and late relapse CLL 
 patients.
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Objectives: Prostate cancer (PC) is the most common cancer in Western countries. 
Recent advances in the treatment of metastatic castration resistant prostate cancer 
(mCRPC) have caused significant pressure on health care budgets. We aimed to 
exemplify this dilemma presenting an example, radium-223 (Xofigo®), and review 
the literature on health technology assessments (HTA), cost-effectiveness analy-
sis (CEA) and guidelines. MethOds: A 74-year-old man diagnosed with mCRPC 
was referred to the Department of Radiology, University Hospital of North Norway 
(UNN) in October 2014 for radium-223 therapy. We faced the following dilemma: is 
radium-223 standard therapy? Is it cost-effective? Medline was searched employing 
the following search criteria: “radium-223”, “alpharadin”, “Xofigo” and “prostate”. 
Exclusion and inclusion criteria were applied. Guidelines and CEAs were focused. 
We also searched the websites of ASCO, ESMO and ISPOR. The web was searched, 
using Yahoo and Google search engines, for Health Technology Assessments 
(HTAs). Results: 181 publications were identified in the Medline database. Only 
health outcomes and cost-savings when used as prophylaxis of FN in patients with 
solid tumors or lymphoma receiving chemotherapy.
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Objectives: To conduct a cost-effectiveness assessment of obinutuzumab/chloram-
bucil (G-Clb) vs rituximab/chlorambucil (R-Clb) in treatment of chronic lymphocytic 
leukemia (1st line treatment) among elderly patients with coexisting conditions in 
the Russian Federation. MethOds: To conduct present study there was developed a 
special model (time horizon – 36 months). All necessary data was obtained from CLL 
11. Effectiveness analysis was based on the following criteria – number of life years. 
Cost analysis included only direct costs on the treatment of CLL (1st line: G-Clb or 
R-Clb, 2nd and 3rd lines – Bendamustin-Rituximab) and severe adverse events. Cost 
data was based on median prices for medicines and medical services in National 
healthcare system in the Russian Federation. Results: Total costs per patient in 
the group of G-Clb were 3217189 rubbles (€ 59688) and for R-Clb - 3102020 rubbles 
(€ 57552). The number of life years for G-Clb was 2,88 and for R-Clb - 2,75. Cost-
effectiveness ratio for G-Clb was 1116724 (€ 20719) and for R-Clb was 1129204 rubbles 
(€ 20950). cOnclusiOns: Due to the lower cost-effectiveness ratio, the use of G-Clb 
instead of R-Clb in treatment of CLL among elderly patients with coexisting conditions 
in the Russian Federation is more reasonable from a pharmacoeconomic point of view.
PCN170
Cost-effeCtiveNess aNalysis of Cetuximab aND PaNitumumab for 
first liNe treatmeNt of metastatiC ColoreCtal CaNCer (mCrC) iN Wt 
ras PatieNts iN sPaiN
Suarez J
Merck, Madrid, Spain
Objectives: The recent indication adjustment of anti-EGFR antibodies cetuximab 
and panitumumab according to RAS biomarker evidences the need to update their 
incremental cost-effectiveness ratios (ICER) as first line therapies in WT RAS mCRC 
patients. MethOds: Literature review about overall survival (OS) with both anti-
bodies in WT RAS mCRC patients. Analysis from the hospital pharmacy’s point of 
view of the cost of life year gained (LYG) based on the results of effectiveness in the 
published reviews for each therapy. The review of the specifications data sheets and 
clinical practice guidelines were used to establish the frequency of administration 
whereas dose regimen was calculated considering the standard values for weight 
as 70kg and body surface as 1.79m2. Results: CRYSTAL trial shows a difference 
of 8.2 months in OS for cetuximab +FOLFIRI vs FOLFIRI (28.4m vs 20.2m; HR: 0.69; 
p= 0.0024), while PRIME trial estimates a profit of 5.8m for panitumumab+FOLFOX 
vs FOLFOX (26.0m vs 20.2m; HR: 0.78; p= 0.04) and FIRE 3 study finds a difference of 
8.1m for cetuximab+FOLFIRI vs bevacizumab+FOLFIRI (33.1m vs 25.0m; HR: 0.697; 
p= 0.0059). The ICER for cetuximab+FOLFIRI vs FOLFIRI is estimated in 27,215€ /
LYG vs 35,367€ /LYG for panitumumab+FOLFOX vs FOLFOX and 5,162€ /LYG for 
cetuximab+FOLFIRI vs bevacizumab+FOLFIRI. During the execution of this analysis, 
the complete results of the CALGB-80405 clinical trial were not available and thus 
were not included in this evaluation. cOnclusiOns: Cetuximab is the biological 
therapy which optimizes the OS and minimizes the cost per LYG in first line treat-
ments for wt RAS patients, with a lower ratio than the usual 30,000 € /LYG threshold. 
These results are in line with the recent decisions of the National Cancer Drugs Fund 
about biological therapies in mCRC (NHS, January and March 2015).
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Objectives: To perform a cost-effectiveness analysis of Panitumumab+FOLFOX 
as first-line treatment in mCRC WT-RAS patients compared to 
Cetuximab+FOLFIRI. MethOds: A seven health stages Markov Model (progression-
free, metastasis resection, second-line progression, palliative care, no-progression 
after resection, progression after resection, and death) were evaluated in two-week 
transition cycles in a lifetime scenario. Since no head to head trials have been con-
ducted comparing Panitumumab and Cetuximab in first line treatment of WT RAS 
patients, an indirect comparison was performed to obtain the relative Progression-
free survival (PFS) and global survival (OS) between both epidermal growth fac-
tor receptor inhibitors (anti-EGFR). By linking PEAK and FIRE-3 trials (assuming 
that FOLFOX and FOLFIRI are equal) via a common evidence base (in this case 
Bevacizumab). Parametric survival modeling was used to extrapolate beyond the 
data collection period. The resource use and treatment patterns were obtained from 
three oncologists through a modified Delphi panel. Costs include testing for RAS 
mutation status; drug administration, chemotherapy, clinician visits, and diagnos-
tic tests; treating grade 3/4 toxicities; metastasis resection; second-line treatment; 
and palliative care. For all procedures Social Security cost (ISS+30) were applied; 
and SISMED prices for drugs. Clinical costs and benefits are discounted 5% per 
annum. Results: The mean discounted OS derived from the model was 45.3 and 
41.8 months with Panitumumab+FOLFOX6 and Cetuximab+FOLFIRI respectively; 
and a mean discounted PFS of 14.8 and 10.8 months. The total average cost with 
Panitumumab is USD$81,522.32 and USD$80,241.83 with Cetuximab. The longer pre-
dicted survival for a patient treated with Panitumumab result in a lower cost per life-
year (LY) (USD$21,613.42) compared to Cetuximab (USD$23,036.94). cOnclusiOns: 
Based on the adjusted PEAK-FIRE3 results, Panitumumab showed treatment out-
comes improvement vs Cetuximab for WT-RAS patients at a lower cost per life year.
